Emerging MEK inhibitors. (Q37691441)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Emerging MEK inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Paolo Lunghi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Massimo Libra

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Giuseppe Montalto

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ferdinando Nicoletti

12

1 reference

ORCID Public Data File 2021

Linda S Steelman

2

object named as

Linda S Steelman

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

14

Alberto M Martelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

4

William H Chappell

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

11

Franca Stivala

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

7

Michele Milella

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

8

Agostino Tafuri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

10

Antonio Bonati

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

16

Melchiorre Cervello

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Steven L Abrams

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Suzanne Russo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Roger Ove

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

1 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Emerging Drugs

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

203-223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

cites work

Emerging Raf inhibitors.

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

MAP kinase pathways: the first twenty years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Raf kinases: function, regulation and role in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Ras oncogenes and their downstream targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Oncogenic Braf induces melanocyte senescence and melanoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

The epidermal growth factor receptor gene family as a target for therapeutic intervention in numerous cancers: what's genetics got to do with it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Equitable Allocation of Antiretrovirals in Resource-Constrained Countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Conditional EGFR promotes cell cycle progression and prevention of apoptosis in the absence of autocrine cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Effects of a conditionally active v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and abrogation of cytokine dependency of hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

The complexity of PTEN: mutation, marker and potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Involvement of p53 and Raf/MEK/ERK pathways in hematopoietic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

BRAF signaling and targeted therapies in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Trial offers early test case for personalized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Increased MAPK expression and activity in primary human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Activation of the 41/43 kDa mitogen-activated protein kinase signaling pathway is required for hepatocyte growth factor-induced cell scattering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Signalling responses linked to betulinic acid-induced apoptosis are antagonized by MEK inhibitor U0126 in adherent or 3D spheroid melanoma irrespective of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Cancer and aging: more puzzles, more promises?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

An anti-aging drug today: from senescence-promoting genes to anti-aging pill

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Cancer stem cell and cancer stemloids: from biology to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Program-like aging and mitochondria: instead of random damage by free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Growth stimulation leads to cellular senescence when the cell cycle is blocked

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Rapamycin decelerates cellular senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

Aging-suppressants: cellular senescence (hyperactivation) and its pharmacologic deceleration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

RAF/RAS oncogenes and mismatch-repair status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903282760

10.1517/14728210903282760

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20151845%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference